Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
About Atara Biotherapeutics (ATRA)
Atara Biotherapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative therapies for patients suffering from serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Founded in 2012, the company is named after Atara Ciechanover, whose battle with cancer inspired its mission to empower patients with innovative treatment options. Atara operates in the United States healthcare sector and focuses on advancing cellular immunotherapy platforms to address significant unmet medical needs.
Core Business Areas
Atara specializes in the development of allogeneic T-cell immunotherapies, leveraging groundbreaking research into the role of T-cells and growth factors such as activin and myostatin in disease progression. The company’s product pipeline is centered on addressing the underlying mechanisms of diseases, offering novel solutions for patients with limited or no effective treatment options. Atara’s key areas of focus include:
- Epstein-Barr Virus (EBV)-Targeted Therapies: Leveraging EBV-specific cytotoxic T lymphocytes (CTLs) to treat diseases associated with EBV, including post-transplant lymphoproliferative disease (PTLD).
- CAR-T Cell Therapy: Developing next-generation chimeric antigen receptor (CAR) T-cell therapies, such as ATA3219, to target hematologic malignancies.
- Multiple Sclerosis (MS) and Autoimmune Diseases: Investigating innovative therapies like ATA188 to address progressive forms of MS by targeting EBV-infected B-cells implicated in autoimmune pathogenesis.
Product Pipeline
Atara’s robust pipeline includes several promising product candidates designed to address critical gaps in current medical treatments:
- Tab-cel®: An allogeneic EBV-specific T-cell immunotherapy targeting EBV-associated cancers, currently in advanced clinical trials.
- ATA188: A groundbreaking therapy aimed at treating progressive multiple sclerosis by modulating immune responses to EBV-infected cells.
- ATA3219: A CAR-T platform designed to enhance the efficacy and safety of T-cell therapies for hematologic cancers.
These therapies reflect Atara’s commitment to addressing both rare and prevalent diseases through innovative approaches rooted in cellular biology and immunotherapy.
Collaborations and Research Partnerships
Atara’s strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) underscores its commitment to advancing T-cell immunotherapy research. This partnership focuses on the development of three T-cell product candidates targeting EBV, cytomegalovirus (CMV), and Wilms Tumor 1 (WT1). By combining Atara’s expertise in immunotherapy with MSK’s research capabilities, the company aims to accelerate the development of groundbreaking treatments for cancer and other diseases.
Competitive Landscape
Atara operates in a highly competitive biotechnology landscape, with key competitors including companies specializing in CAR-T therapies, allogeneic cell therapies, and advanced biologics. However, Atara differentiates itself through its focus on allogeneic T-cell platforms, which offer potential advantages in scalability, manufacturing, and cost-effectiveness compared to autologous therapies. Additionally, its emphasis on EBV-targeted therapies positions it uniquely within the immunotherapy space, addressing both oncology and autoimmune indications.
Challenges and Opportunities
While Atara faces challenges such as navigating complex regulatory pathways, achieving clinical trial success, and competing in a crowded biotech market, it also has significant opportunities to establish itself as a leader in allogeneic immunotherapy. By addressing high unmet medical needs and leveraging its innovative pipeline, Atara has the potential to transform treatment paradigms for a range of serious diseases.
Conclusion
Atara Biotherapeutics is at the forefront of cellular immunotherapy, driven by a mission to empower patients with better treatment options. Through its innovative product pipeline, strategic collaborations, and focus on addressing unmet medical needs, Atara is poised to make a meaningful impact in the biotechnology industry. Its commitment to advancing science and improving patient outcomes underscores its significance as a key player in the healthcare sector.
Atara Biotherapeutics (NASDAQ: ATRA) will host an EBV and MS Day on March 22, 2022, from 4:00 p.m. EDT. CEO Dr. Pascal Touchon and the management team will discuss the role of Epstein-Barr virus (EBV) in multiple sclerosis (MS), the development of ATA188, and review Phase 1 clinical data. Renowned experts like Mark Freedman and Lawrence Steinman will provide insights. The event includes a conference call for analysts and investors, with a live webcast available on atarabio.com.
Atara Biotherapeutics (NASDAQ: ATRA) reported granting 45,040 restricted stock units and 39,978 stock options to newly hired employees. These awards were approved by Atara’s Compensation Committee and are part of the 2018 Inducement Plan. The restricted stock units will vest over four years, with 25% vesting on the first anniversary. The stock options have a ten-year term and an exercise price of $10.21 per share. This announcement aligns with Nasdaq Listing Rule 5635(c)(4) requirements.
Atara Biotherapeutics (NASDAQ: ATRA) will have its CEO, Pascal Touchon, participate in a cell therapy panel at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 9:10 a.m. EST. The event emphasizes Atara's leadership in T-cell immunotherapy, particularly leveraging its allogeneic Epstein-Barr virus (EBV) platform for cancer and autoimmune disease treatments. A live webcast will be available on their website, with an archived replay accessible for 30 days post-presentation.
Atara Biotherapeutics (Nasdaq: ATRA) announced that a U.S. BLA submission for tab-cel is not expected in Q2 2022 due to further FDA alignment needed. However, the EU approval is on track for Q4 2022. The company reported a Q4 2021 net loss of $93.3 million and a total operating expense increase of 18% compared to the previous year. Significant advances were made in the development of ATA188 for progressive multiple sclerosis, which has received Fast Track designation from the FDA. Atara also entered a $100 million strategic manufacturing partnership with Fujifilm.
Atara Biotherapeutics (NASDAQ: ATRA) reported a serious adverse event (SAE) related to its autologous mesothelin CAR T therapy, ATA2271, during a Phase 1 study at Memorial Sloan Kettering Cancer Center (MSK). Following this event, MSK temporarily paused patient enrollment in the trial. The SAE involved a patient with prior malignancies and is currently under evaluation. Despite this setback, ongoing IND-enabling work for another CAR-T therapy, ATA3271, is unaffected. Atara emphasizes patient safety and intends to update stakeholders soon.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its fourth quarter and full year 2021 financial results on February 28, 2022. The announcement will be followed by a live conference call at 4:30 p.m. EST to discuss these results and provide a corporate update. Atara aims to deliver T-cell immunotherapy treatments for serious diseases using its unique Epstein-Barr virus T-cell platform, currently advancing several therapies, including tab-cel® for EBV-driven conditions, and ATA188 targeting multiple sclerosis.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 31,730 restricted stock units and stock options for 30,819 shares to new employees under its 2018 Inducement Plan, as per Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25% vesting after the first anniversary, while stock options also vest over four years with an exercise price of $15.47. This strategy aims to attract talent in T-cell immunotherapy to further develop treatments for cancer and autoimmune diseases.
Atara Biotherapeutics (NASDAQ: ATRA) has announced an agreement to sell its T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California, to FUJIFILM Diosynth Biotechnologies for USD 100 million. This strategic deal, which includes a long-term supply agreement, aims to reduce Atara's operating expenses and is expected to fund its operations into Q4 2023. Atara will retain its manufacturing expertise while FDB will expand the site to produce a wider range of allogeneic cell therapies. The deal is anticipated to close in April 2022, pending regulatory approval.
Atara Biotherapeutics (ATRA) announced significant findings linking Epstein-Barr virus (EBV) infection to multiple sclerosis (MS). A recent study published in Nature shows how EBV triggers immune cells to attack the myelin sheath in the central nervous system, potentially causing MS. The research indicates that nearly 100% of MS patients have been infected with EBV. Atara's investigational therapy, ATA188, targets EBV-infected B cells and is currently in a Phase 2 clinical study, highlighting its potential as a treatment option for MS.
Atara Biotherapeutics (NASDAQ: ATRA) announced significant milestones for its T-cell immunotherapies in 2021, including FDA Fast Track designation for ATA188 in multiple sclerosis, enhancing its market position. The company aims for tab-cel® to be the first allogeneic therapy approved in the EU for post-transplant lymphoproliferative disease, with decisions expected in 2022. Key presentations will occur at the J.P. Morgan Healthcare Conference on January 12. The company is also advancing CAR T programs targeting solid tumors. 2022 is projected to be a pivotal year for Atara's drug approvals.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
What does Atara Biotherapeutics specialize in?
What is the focus of Atara’s product pipeline?
How does Atara differentiate itself from competitors?
What are Atara’s key collaborations?
What challenges does Atara Biotherapeutics face?
What is Tab-cel®?
What is ATA188, and what does it treat?
What diseases does Atara aim to address?
